Granules India Q2 Review - Q2 Performance Below Expectations: Centrum Broking

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Centrum Broking Report.Granules India Ltd.'s Q2 performance was below our estimates. Revenue grew 4% year-on-year and 5% quarter-on-quarter. The headwinds on RM supplies impacted performance along with disrupted demand.GIL partially began procurement of PAP domestically. We expect capacity utilisation to improve further though we believe demand normalisation would only happen beyond FY23. Management is hopeful on gradual improvement in realisation over H2, as GIL passes increased costs to customers. We look forward to niche launches and MUPS-based product ramp-up in the U.S. beyond H2FY23. The headwinds led to guidance miss this year and we believe normalisation would be gradual..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Granules India Q2 Review - Q2 Performance Below Expectations: Centrum Broking

Granules India Q2 Review - Q2 Performance Below Expectations: Centrum Broking

Choose a plan